Shares of CryoLife Inc. (NYSE:CRY) reached a new 52-week high on Tuesday . The company traded as high as $14.80 and last traded at $14.78, with a volume of 83,742 shares traded. The stock had previously closed at $14.34.

CRY has been the topic of a number of recent research reports. Canaccord Genuity initiated coverage on shares of CryoLife in a research note on Wednesday, April 13th. They set a “buy” rating and a $14.00 target price on the stock. Piper Jaffray Cos. restated an “overweight” rating and set a $15.00 target price on shares of CryoLife in a research note on Thursday, April 21st. Lake Street Capital initiated coverage on shares of CryoLife in a research note on Wednesday, June 15th. They set a “buy” rating and a $15.00 target price on the stock. Zacks Investment Research lowered shares of CryoLife from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 5th. Finally, Ladenburg Thalmann lowered shares of CryoLife from a “buy” rating to a “neutral” rating and set a $12.00 target price on the stock. in a research note on Thursday, April 28th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $14.20.

The company’s 50-day moving average is $12.69 and its 200 day moving average is $11.51. The company has a market cap of $500.39 million and a P/E ratio of 47.02.

CryoLife (NYSE:CRY) last posted its quarterly earnings results on Monday, July 25th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.02 by $0.11. The business earned $47.10 million during the quarter, compared to analysts’ expectations of $35.50 million. The firm’s quarterly revenue was up 32.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.03 EPS. Equities research analysts anticipate that CryoLife Inc. will post $0.24 EPS for the current fiscal year.

In other news, Director C Elkins Ronald sold 2,000 shares of CryoLife stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $14.00, for a total value of $28,000.00. Following the transaction, the director now directly owns 103,586 shares of the company’s stock, valued at approximately $1,450,204. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronald D. Mccall sold 10,000 shares of CryoLife stock in a transaction dated Wednesday, June 1st. The shares were sold at an average price of $11.56, for a total value of $115,600.00. Following the completion of the transaction, the director now directly owns 156,248 shares in the company, valued at $1,806,226.88. The disclosure for this sale can be found here.

An institutional investor recently raised its position in CryoLife stock. Morgan Stanley boosted its stake in shares of CryoLife Inc. (NYSE:CRY) by 1.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,605,563 shares of the company’s stock after buying an additional 21,067 shares during the period. Morgan Stanley owned about 5.64% of CryoLife worth $17,308,000 at the end of the most recent quarter.

CryoLife, Inc (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.